Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011))

Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY (2021)

Publication Type: Journal article, Erratum

Publication year: 2021

Journal

DOI: 10.1016/j.breast.2020.12.007

Abstract

In Fig. 2c and f of our publication Schneeweiss et al. [1] we mistakenly placed wrong Kaplan Meier Plots. In the attached figure this was corrected. All other estimates concerning the survival including the regression models are correct. We apologize for the mistake. 1. Schneeweiss A, Ettl J, Luftner D et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88–95.Fig. 2. Progression-free survival (PFS) and overall survival (OS) for the total group analyzed. CDK4/6i, CDK4/6 inhibitors; ET, endocrine therapy; OS, overall survival; PFS, progression-free survival. [Table presented]

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Düsseldorf Germany (DE) ClinSol GmbH & Co.KG Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Marienhospital Bottrop Germany (DE) Praxisklinik am Rosengarten Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) Universitätsklinikum Ulm Germany (DE) Klinikum rechts der Isar Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Frankfurter Hormon und Osteoporosezentrum Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Martin-Luther-Universität Halle-Wittenberg (MLU) Germany (DE) Klinikum der Universität München Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Agaplesion Markus Krankenhaus Germany (DE) HELIOS Kliniken Germany (DE) Oncologianova GmbH Germany (DE) Gynäkologie Kompetenzzentrum Stralsund: gSUND Germany (DE) Medizinisches Zentrum Bonn Friedensplatz Germany (DE)

How to cite

APA:

Schneeweiss, A., Ettl, J., Lüftner, D., Beckmann, M., Belleville, E., Fasching, P.,... Brucker, S.Y. (2021). Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)). BREAST . https://doi.org/10.1016/j.breast.2020.12.007

MLA:

Schneeweiss, Andreas, et al. "Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011))." BREAST (2021).

BibTeX: Download